Publications

October, 2021

CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial

Presented at the 2021 Annual NEALS Meeting
January, 2021

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Published in Stem Cell Research & Therapy
August, 2020

Effects of MSC-NTF cells on T and B regulatory cell function in ALS

Published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
November, 2019

NurOwn, phase 2, randomized, clinical trial in patients with ALS

Published in Neurology
May, 2019

Phase 2 Open-Label, Multicenter Study of Repeated Intrathecal Administration of Autologous MSC-NTF cells in Progressive Multiple Sclerosis

Presented at the 2019 Annual CMSC Meeting
May, 2019

Molecular Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS

Presented at the 2019 Annual AAN Meeting
May, 2019

Modulation of CSF Caspase-3 in MSC-NTF Cells (NurOwn®) in a Phase 2 ALS Study: Correlations with CSF Biomarkers and Clinical Response

Presented at the 2019 Annual AAN Meeting
December, 2018

A Systematic Review of Enrichment Strategies for Current Clinical Trials in ALS

Presented at the International Symposium on ALS/MND
October, 2018

MicroRNA Changes in the NurOwn® Phase 2 ALS Randomized Clinical Trial: Relationship to Neuroprotection and Innate Immunity

Presented at the Annual NEALS Conference
April, 2018

Modulation of CSF miRNAs in ALS Phase 2 Study Participants Treated With MSC-NTF Cells (NurOwn®)

Presented at the Annual AAN Meeting
April, 2018

NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains

Presented at the Annual AAN Meeting
November, 2017

miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors

Stem Cell Research & Therapy
January, 2016

Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis

Published in JAMA Neurology
2017

Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism

Behavioural Brain Research
2017

Concise review: Mesenchymal stem cells in neurodegenerative diseases

Stem Cells
2014

Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells

Clin Transl Med
2014

Rare combination of myasthenia and motor neuronopathy, responsive to MSC-NTFstem cell therapy

Muscle Nerve
2012

Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2…

PLoS Curr
2012

Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington’s disease

Exp Neurol
2012

Differentiated mesenchymal stem cells for sciatic nerve injury

Exp Neurol
2010

Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection

Invest Ophthalmol Vis Sci.
2009

Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in…

J Mol Neurosci
2009

Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease

Stem Cells and Development
2009

Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases

Isr Med Assoc J
2009

Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease

J Mol Neurosci
2008

Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging

Stem Cells
Scroll to Top